Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies how well cadonilimab combined with anlotinib and docetaxel
work in treating patients with non-small cell lung cancer that is stage IV or has come back.
Cadonilimab, a PD-1/CTLA-4 bispecific antibody, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Anlotinib can
regulate tumor microenvironment. Docetaxel was used in standard of care chemotherapy for
non-small cell lung cancer, work to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving
cadonilimab, anlotinib and docetaxel together may work better in treating patients with
non-small lung cancer compared to standard of care.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shanghai Chest Hospital
Collaborators:
Anhui Provincial Hospital The Affiliated Hospital of Qingdao University Zhejiang University